Investing in royalty companies—particularly within the mining, pharmaceutical, or intellectual property sectors—is widely regarded as an attractive strategy because it offers high profit margins, operational leverage, and built-in diversification without direct exposure to operating costs, capital expenditure overruns, or labor disputes. Royalty holders collect a percentage of top-line revenue or sales. However, investors must still contend with underlying asset performance risks, such as unexpected production stoppages, depletion of reserves, or partner management issues that can impact the reliability of future royalty cash flows.